MARÍA ISABEL
BLANCAS LÓPEZ-BARAJAS
PROFESORA ASOCIADA LABORAL
José Manuel
Baena Cañada
José Manuel Baena Cañada-rekin lankidetzan egindako argitalpenak (4)
2021
-
Real-world data of fulvestrant as first-line treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer
Scientific Reports, Vol. 11, Núm. 1
2019
-
Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study
Breast Cancer Research and Treatment, Vol. 177, Núm. 1, pp. 115-125
2018
-
Correction to: Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice (Clinical and Translational Oncology, (2018), 20, 7, (862-869), 10.1007/s12094-017-1797-9)
Clinical and Translational Oncology
-
Efficacy of fulvestrant in the treatment of postmenopausal women with endocrine-resistant advanced breast cancer in routine clinical practice
Clinical and Translational Oncology, Vol. 20, Núm. 7, pp. 862-869